EU and US could reach trade deal this weekend - Reuters
On Wednesday, H.C. Wainwright reaffirmed a positive outlook on Compass Pathways (NASDAQ:CMPS), maintaining a Buy rating and a $45.00 price target. Currently trading at $3.85, the stock sits well below analyst targets ranging from $11 to $45, with a strong Buy consensus rating of 1.3. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The optimism stems from the potential of COMP360™, the company’s investigational psilocybin therapy for treatment-resistant depression (TRD). Analysts at the firm highlight COMP360’s rapid efficacy, possible lasting effects, and scalability as key advantages over existing treatments such as SPRAVATO (esketamine).
Compass Pathways is not only concentrating on TRD but is also planning to expand its research to include post-traumatic stress disorder (PTSD), with a larger Phase 2b trial anticipated to commence later in 2023. Additionally, the company is expected to release data from a Phase 2 trial in anorexia nervosa later in 2025. The financial position of Compass Pathways was bolstered by a $140 million financing round announced on January 10, which is projected to fund operations into 2026, supporting both TRD and PTSD research. InvestingPro data shows the company maintains a strong current ratio of 5.92 and holds more cash than debt on its balance sheet, though it remains unprofitable with a -$156.88M EBITDA over the last twelve months.
Strategic collaborations with interventional psychiatry networks are being established to lay the foundation for commercial success. H.C. Wainwright’s analysts suggest that COMP360 has the potential to be a blockbuster treatment if it gains approval. They believe the current market valuation of $356 million does not fully account for the drug’s prospects in addressing several major psychiatric disorders. The firm’s reiterated rating and price target reflect their confidence in the future commercial potential of COMP360. For deeper insights into CMPS’s valuation and growth potential, explore the comprehensive Pro Research Report available on InvestingPro, which provides detailed analysis of the company’s financial health and market position.
In other recent news, Compass Therapeutics reported a Q4 adjusted loss per share of -$0.11, which was slightly below analyst estimates of -$0.10, and did not report any revenue for the quarter. For the full year 2024, the company posted a net loss of $49.4 million or -$0.36 per share, compared to a loss of $42.5 million or -$0.33 per share in 2023. Despite these figures, the company highlighted advancements in its pipeline, particularly with its lead candidate, tovecimig, which is on track for a key data readout by the end of Q1 2025. Compass expects top-line results from the COMPANION-002 trial evaluating tovecimig in biliary tract cancer patients. An investigator-sponsored study of tovecimig in first-line biliary tract cancer is also set to begin patient dosing in Q1 2025. Additionally, Compass is advancing its CTX-10726 program, a PD-1 x VEGF-A bispecific antibody expected to enter clinical trials in 2026. The company ended 2024 with $127 million in cash and marketable securities, which it anticipates will fund operations into Q1 2027. Compass plans to initiate new Phase 2 trials for tovecimig and CTX-471 in mid-2025, focusing on novel biomarkers to target specific patient populations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.